Assetmark Inc. Lowers Stock Holdings in Kenvue Inc. $KVUE

Assetmark Inc. reduced its position in Kenvue Inc. (NYSE:KVUE) by 49.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,174 shares of the company’s stock after selling 53,749 shares during the quarter. Assetmark Inc.’s holdings in Kenvue were worth $895,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Salomon & Ludwin LLC acquired a new position in shares of Kenvue in the third quarter valued at approximately $25,000. NBT Bank N A NY boosted its position in Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after buying an additional 1,006 shares during the period. Cornerstone Planning Group LLC boosted its position in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after buying an additional 1,361 shares during the period. Golden State Wealth Management LLC grew its stake in shares of Kenvue by 150.1% in the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after acquiring an additional 1,190 shares in the last quarter. Finally, Trust Co. of Vermont increased its position in shares of Kenvue by 50.9% during the third quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock worth $39,000 after acquiring an additional 804 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Price Performance

Shares of NYSE KVUE opened at $18.73 on Friday. The stock’s 50-day simple moving average is $17.54 and its 200-day simple moving average is $17.65. The firm has a market capitalization of $35.88 billion, a PE ratio of 24.32 and a beta of 0.59. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a return on equity of 19.86% and a net margin of 9.72%.The firm had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same period in the prior year, the company posted $0.26 earnings per share. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th will be given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend is Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is 107.79%.

Insider Buying and Selling

In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of Kenvue stock in a transaction that occurred on Friday, December 12th. The stock was purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.68% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on KVUE. Evercore set a $18.00 target price on Kenvue in a report on Tuesday, October 28th. UBS Group lifted their price objective on Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $23.00 to $18.00 in a research report on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Finally, Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Four equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $20.08.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.